Alpha-fetoprotein (AFP) is a protein primarily produced by the liver of a developing fetus. In adults, it is measured to help diagnose liver diseases, such as cirrhosis or liver cancer, and to monitor fetal development during pregnancy. Elevated AFP levels in adults can indicate liver issues, while abnormal AFP levels during pregnancy may suggest potential birth defects, such as neural tube defects. This test is valuable for assessing liver health and monitoring fetal well-being.
The CA 125 test measures the level of a protein in the blood that can be elevated in ovarian cancer and other conditions. It is used to monitor ovarian cancer, evaluate treatment effectiveness, and detect recurrence. Since elevated CA 125 levels can also occur in non-cancerous conditions, the test is typically combined with other diagnostic tools for accurate results.
The CA 19-9 test measures the level of a protein that can be higher in certain cancers, especially pancreatic cancer, as well as in colorectal or stomach cancer. It may also be elevated in non-cancerous conditions like liver disease or pancreatitis. This test is useful for monitoring treatment, checking for cancer recurrence, and helping diagnose cancer when used with other tests.
CA 50 is a blood test used to measure the level of cancer antigen 50, a protein found on the surface of certain cancer cells. It is primarily used as a tumor marker for pancreatic cancer but may also be elevated in other cancers, such as colorectal, ovarian, and gastric cancers. Elevated CA 50 levels can indicate cancer or non-cancerous conditions like liver disease or pancreatitis. This test is commonly used to monitor known cancer patients, assess treatment effectiveness, or check for recurrence, but it is not specific enough to be used as a primary screening test for cancer.
Carcinoembryonic Antigen (CEA) is a protein typically found in low levels in healthy adults, but its levels can be elevated in the blood due to certain cancers and some non-cancerous conditions. It is commonly used as a tumor marker, especially for colon and rectal cancers, and may also be elevated in cancers of the lung, breast, pancreas, stomach, and thyroid.
The Cancer Screening Women is designed to offer essential insights into potential cancer risks by assessing key biomarkers associated with ovarian, gastrointestinal, and liver cancers. This screening focuses on detecting early signs and providing proactive health management.
The test includes Alpha-fetoprotein (AFP), a biomarker linked to liver cancer and other malignancies, CA 125, which is primarily used for ovarian cancer detection, and CA 19-9, a marker for gastrointestinal cancers. Additionally, it includes CA 50, which can indicate the presence of gastrointestinal and pancreatic cancers, and Carcinoembryonic Antigen (CEA), a marker often elevated in cases of colorectal cancer.
This screening is an essential tool for women looking to monitor their health, detect potential cancer risks, and take steps toward early intervention.